by Stacey Johnson | Nov 27, 2015
To some people, November is now Movember. That is testament to how successful and pervasive this campaign for men’s health – especially prostate cancer – has become. (Blogger Sara Nolte has also chosen to write about prostate cancer during Movember.) Last month the...
by David Kent | Nov 16, 2015
The United Kingdom has begun its foray into using cells derived from human embryonic stem cells (ESCs) in clinical settings. I have to admit I was surprised that following coverage on the BBC and in The Guardian, there was virtually no anti-ESC protesting to be found,...
by Mark Curtis | Oct 27, 2015
Welcome to your Update from the Clinic for the month of September. OncoSec Medical released some initial data from its Phase 1/2 study investigating ImmunoPulse IL-12 DNA in a rare skin cancer. Pluristem and the National Institute of Allergy and Infectious Diseases...
by Mark Curtis | Oct 20, 2015
. Welcome to your Cell Therapy Deal Review for the month of September. Aduro Biotech went the way of Juno and Kite and bought an antibody discovery platform. Intrexon and ZIOPHARM entered into an agreement to develop a novel Treg-based immunotherapy for GvHD. Kite...
by Erin Sugar | Oct 9, 2015
. When he’s not roaming hospital corridors, Dr. Adnan Khera, an anesthesiology resident at Boston’s Tufts Medical Center, can be found dancing on the city streets two nights a week. But he’s not dancing for fame, he’s earning money for his charity “Doctor Be...
by Mark Curtis | Sep 30, 2015
. Welcome to your cell therapy deal review for the month of August. Synthetic biology giant Intrexon closed a large financing; Immune Design announced a collaboration to pair its viral-based immunotherapy platform with a checkpoint inhibitor; and, NantKwest received a...
Comments